Cardio Diagnostics Holdings (CDIO) Construction in Progress (2023 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Construction in Progress of $502155.0 for Q1 2026, little changed sequentially from $502155.0 in Q4 2025, and little changed YoY from $502155.0 in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Construction in Progress (2023 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Construction in Progress for 4 years, with the latest figure at $502155.0 in Q1 2026.
- Quarterly Construction in Progress changed 0.0% year-over-year to $502155.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $502155.0 (changed 0.0% YoY) and the FY2025 annual result came in at $502155.0, changed 0.0% from the prior year.
- Construction in Progress steadied at $502155.0 in Q1 2026 per CDIO's latest filing, from $502155.0 in the prior quarter.
- Over five years, Construction in Progress peaked at $502155.0 in Q1 2024 and troughed at $482170.0 in Q4 2023.
- A 4-year average of $500156.5 and a median of $502155.0 in 2024 frame the typical range for Construction in Progress.
- The sharpest annual moves came in 2024 and 2025: Construction in Progress grew 4.14% in 2024, then changed 0.0% in 2025.
- Over 4 years, Construction in Progress stood at $482170.0 in 2023, then climbed by 4.14% to $502155.0 in 2024, then changed by 0.0% to $502155.0 in 2025, then changed by 0.0% to $502155.0 in 2026.
- According to Business Quant data, Construction in Progress over the past three periods registered $502155.0, $502155.0, and $502155.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 152.67 Mn |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | Cardio Diagnostics Holdings | 6.03 Mn | 443,812.80 | - | 502,155.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 502,155.00 |
| Mar 31, 2026 | 502,155.00 |
| Dec 31, 2025 | 502,155.00 |
| Sep 30, 2025 | 502,155.00 |
| Jun 30, 2025 | 502,155.00 |
| Mar 31, 2025 | 502,155.00 |
| Dec 31, 2024 | 502,155.00 |
| Sep 30, 2024 | 502,155.00 |
| Jun 30, 2024 | 502,155.00 |
| Mar 31, 2024 | 502,155.00 |
| Dec 31, 2023 | 482,170.00 |